Pharmaceutical filing citing Cell paper — HCW Biologics, 2026-05-27
HCW BiologicsHCW BiologicsNASDAQ HCWB
Filings SEC · Quote Yahoo cited a paper published in Cell in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type and written down. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the report submitted to the Securities and Exchange Commission is called 8-K. The item number of the document submitted by HCW Biologics on 2026-05-27 was 1.02 Termination of Important Contract · 9.01 Financial Statements·Attached Documents. The company cited a paper published in Cell in the attached press release. The sentence citing the paper, copied verbatim from the original, is as follows.
Wugen held exclusive worldwide rights to these two compounds for ex vivo, cell-based therapy applications. The Company acquired these rights for no cost and retained the nonrefundable upfront license fee, including 2.2 million shares of Wugen common stock.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which reads only the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract is limited to this extent.
The paper title is Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse and it was published in Cell on 2026-04-30. The authors' affiliations are University Hospital Regensburg · University of Regensburg · Leibniz Institute for Immunotherapy · IRCCS Humanitas Research Hospital. The summary published at the beginning of the paper is called abstract. What this article has read is only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and original judgment.
This is the first patient-targeted trial in which CD19 CAR-T made from the donor's T cells was administered to patients with B-cell blood cancer that recurred after bone marrow transplantation. CAR-T made from early-stage cells called stem cell memory T cells increased more in the body and remained longer than standard CAR-T, and complete responses were achieved at low doses without pre-treatment to remove lymphocytes. The cytokine release syndrome, a severe immune reaction, was mild, and when the treatment was ineffective, the main causes were factors related to the tumor and the patient rather than the cells themselves. The number of patients treated and how long the complete responses lasted are not mentioned in the abstract.
What the abstract does not answer remains in the full text and the appendix. This article leaves the blanks as they are. Readers can determine which sentence in the abstract corresponds to the quoted text cited by the company by comparing the two citations above.
A month later, the stock price was within the bottom quarter of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The dates are counted in trading days, which are only the days the stock market is open. In terms of the calendar, 20 trading days are approximately one month. The excess returns for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | +113.8% | The extent of movement before the filing |
| On the filing date | −26.2% | On the filing date or the first trading day afterward |
| Cumulative over +1 to +5 trading days | −38.8% | One week |
| Cumulative over +1 to +20 trading days | −48.4% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -48.4% in this case is within the bottom quarter, at the 4% level from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.8% | −20.1% | −6.9% | +5.5% | +19.5% | −48.4% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample collects cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules applicable to future cases.
After the filing, the company issued such documents.
Three 8-K filings issued by the company after the filing date are listed with only item numbers. In 8-K filings without titles, the item number indicates the type of content. One can determine whether it was an earnings announcement or a contract based on the number. The specific event is described in the original text linked.
- 2026-06-01 8-K Item 3.01 —
- 2026-06-15 8-K Item 5.07 — Results of the Shareholders' Meeting
- 2026-06-16 8-K Item 7.01, 9.01 — Reg FD Disclosure · Financial Statements · Exhibits
What this article does not answer
This article, based on abstracts, cannot answer what method the paper used, what it reviewed, or what it demonstrated. How often the cited paper was referenced afterward can be verified again using the citation count from OpenAlexOpenAlex
Data source · Website. What will be examined next is whether the company's subsequent 8-K filing cites the same paper again.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform shareholders. Types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement of the company alone by removing the part where the market rises and falls together.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days are about a month in the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full paper, one cannot know the details and limitations of the method.